{"name":"mAbxience Research S.L.","slug":"mabxience-research-sl","ticker":"","exchange":"","domain":"mabxienceresearchsl.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":10,"colorKey":"oncology","drugs":[{"name":"EU-sourced Xgeva","genericName":"EU-sourced Xgeva","slug":"eu-sourced-xgeva","indication":"Other","status":"phase_1"},{"name":"MB04","genericName":"MB04","slug":"mb04","indication":"Other","status":"phase_1"},{"name":"US-Synagis®","genericName":"US-Synagis®","slug":"us-synagis","indication":"Other","status":"phase_1"},{"name":"EU Source Enbrel","genericName":"EU Source Enbrel","slug":"eu-source-enbrel","indication":"Other","status":"phase_1"},{"name":"MB02","genericName":"MB02","slug":"mb02","indication":"Other","status":"phase_1"},{"name":"MB09","genericName":"MB09","slug":"mb09","indication":"Other","status":"phase_1"},{"name":"US License Enbrel","genericName":"US License Enbrel","slug":"us-license-enbrel","indication":"Other","status":"phase_1"},{"name":"US licenced Avastin®","genericName":"US licenced Avastin®","slug":"us-licenced-avastin","indication":"Other","status":"phase_1"},{"name":"US- sourced Opdivo®","genericName":"US- sourced Opdivo®","slug":"us-sourced-opdivo","indication":"Other","status":"phase_3"},{"name":"US-sourced Xgeva","genericName":"US-sourced Xgeva","slug":"us-sourced-xgeva","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"EU-approved Avastin®","genericName":"EU-approved Avastin®","slug":"eu-approved-avastin","indication":"Metastatic colorectal cancer","status":"phase_3"},{"name":"EU-Opdivo®","genericName":"EU-Opdivo®","slug":"eu-opdivo","indication":"Metastatic non-small cell lung cancer","status":"phase_3"},{"name":"MB09 (denosumab biosimilar)","genericName":"MB09 (denosumab biosimilar)","slug":"mb09-denosumab-biosimilar","indication":"Prevention of skeletal-related events in patients with bone metastases from solid tumors","status":"phase_3"},{"name":"RTXM83","genericName":"RTXM83","slug":"rtxm83","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"}]}],"pipeline":[{"name":"EU-sourced Xgeva","genericName":"EU-sourced Xgeva","slug":"eu-sourced-xgeva","phase":"phase_1","mechanism":"Binds to and inhibits RANKL, preventing osteoclast formation and bone resorption.","indications":[],"catalyst":""},{"name":"MB04","genericName":"MB04","slug":"mb04","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"EU-approved Avastin®","genericName":"EU-approved Avastin®","slug":"eu-approved-avastin","phase":"phase_3","mechanism":"Avastin (bevacizumab) is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients.","indications":["Metastatic colorectal cancer","Metastatic non-small cell lung cancer","Metastatic breast cancer","Glioblastoma","Metastatic renal cell carcinoma"],"catalyst":""},{"name":"US-Synagis®","genericName":"US-Synagis®","slug":"us-synagis","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"EU Source Enbrel","genericName":"EU Source Enbrel","slug":"eu-source-enbrel","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"EU-Opdivo®","genericName":"EU-Opdivo®","slug":"eu-opdivo","phase":"phase_3","mechanism":"EU-Opdivo® is a PD-1 checkpoint inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses.","indications":["Metastatic non-small cell lung cancer","Melanoma","Renal cell carcinoma","Hodgkin lymphoma","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"MB02","genericName":"MB02","slug":"mb02","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MB09","genericName":"MB09","slug":"mb09","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MB09 (denosumab biosimilar)","genericName":"MB09 (denosumab biosimilar)","slug":"mb09-denosumab-biosimilar","phase":"phase_3","mechanism":"MB09 is a biosimilar of denosumab that inhibits RANKL (receptor activator of nuclear factor kappa-B ligand) to suppress osteoclast formation and bone resorption.","indications":["Prevention of skeletal-related events in patients with bone metastases from solid tumors","Treatment of osteoporosis in postmenopausal women and men at high risk of fracture","Giant cell tumor of bone"],"catalyst":""},{"name":"RTXM83","genericName":"RTXM83","slug":"rtxm83","phase":"phase_3","mechanism":"RTXM83 is a monoclonal antibody targeting PD-L1.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""},{"name":"US License Enbrel","genericName":"US License Enbrel","slug":"us-license-enbrel","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"US licenced Avastin®","genericName":"US licenced Avastin®","slug":"us-licenced-avastin","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"US- sourced Opdivo®","genericName":"US- sourced Opdivo®","slug":"us-sourced-opdivo","phase":"phase_3","mechanism":"Opdivo is a PD-1 inhibitor that works by blocking the PD-1 receptor on T cells, allowing them to attack cancer cells.","indications":[],"catalyst":""},{"name":"US-sourced Xgeva","genericName":"US-sourced Xgeva","slug":"us-sourced-xgeva","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":14,"phaseCounts":{"phase_1":9,"phase_3":5},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}